Archive | July, 2012

Blog mining in reduced dimensions

Despite exaggerated predictions about the death of the blog, it seems numbers continue to grow. Everyone and their dog seems to want to share their innermost thoughts, echo the news and comment on everything from the Higgs Boson to the Gaga Biebon. Efficiently pulling useful information from the millions of blogs with all their various […]

Continue Reading

Recession….What Recession? CEO Pay Continues to Skyrocket

Massive numbers of public and private employees have lost their jobs in the past five years.USunemployment still hovers around 8.0% but yet corporate profits have been hitting historical highs for the past two years. And, not surprisingly, CEOs are milking those profits for as much as they can get. To be fair, some public companies […]

Continue Reading

Revolutions: Paving the way for the Bioeconomy

Logos Press has just published a new book by Randall Mayes. Revolutions: Paving the Way for the Bioeconomy is an in-depth look at the increasing impact of biology primarily due to the potential of genomics. The book focuses on four revolutions: Industrial Revolutions Genomics researchers hope to launch personalized medicine and cure diseases by identifying […]

Continue Reading

Be wary of miracles too good to be true

Not for the first time I’ve suspected that lyricist and drummer with the Canadian rock band Rush, Neil Peart has been reading my blog. First time was having written about the concept of earthshine, the band’s next album featured a song on that very concept, the reflected light from the Earth illuminating the dark face […]

Continue Reading

Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout…

Pharmos Corporation,  announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (5S)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine, S-tofisopam see structure below) to treat patients with hyperuricemia and gout. This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, MD, PhD, an expert and key […]

Continue Reading